氟氯西林是健康成人及原代人肝细胞3D球体中CYP3A4的弱诱导剂
结果显示氟氯西林降低咪达唑仑代谢比(CYP3A4),10天GMR 0.75(95%CI 0.64-0.89),28天GMR 0.72(95%CI 0.62-0.85),且不改变自身血浆浓度;3D球体中浓度依赖性诱导CYP3A4、CYP2B6等。结论为氟氯西林是CYP3A4弱诱导剂,可能对窄治疗窗CYP3A4底物药物产生临床相关药物相互作用。
要点
- 氟氯西林是CYP3A4弱诱导剂,可降低咪达唑仑代谢比。
- 氟氯西林不诱导自身代谢,27天治疗期间血浆浓度无变化。
- 与窄治疗窗CYP3A4底物合用时需警惕药物相互作用。
核心结论
- 氟氯西林是CYP3A4的弱诱导剂,可能对某些窄治疗窗CYP3A4底物药物导致临床相关药物相互作用。
研究设计与样本
- 受试者口服氟氯西林1 g每日三次共31天,在第0、10、28天评估Basel鸡尾酒药物全套药代动力学,第0、9、27天测氟氯西林血浆浓度。
- 原代人肝细胞3D球体暴露于氟氯西林(浓度范围0.15-250 μM)96小时,评估CYP酶mRNA表达、蛋白丰度和酶活性诱导。
主要发现
- 氟氯西林降低咪达唑仑(CYP3A4)代谢比:10天GMR 0.75(95%CI 0.64-0.89),28天GMR 0.72(95%CI 0.62-0.85)。
- 27天治疗期间氟氯西林血浆浓度无变化。
- 3D球体中原代人肝细胞显示氟氯西林浓度依赖性诱导CYP3A4和CYP2B6(mRNA、蛋白和活性),CYP2C9(mRNA和蛋白),CYP2C19(mRNA和活性),CYP2D6(活性)。
临床怎么用
- 临床使用氟氯西林时,应关注与CYP3A4底物药物(尤其是窄治疗窗药物)的潜在相互作用。
- 对于合用的CYP3A4底物药物,可能需要监测疗效或调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Flucloxacillin is a widely used antibiotic. It is an agonist to the nuclear receptor PXR that regulates the expression of cytochrome P450 (CYP) enzymes. Treatment with flucloxacillin reduces warfarin efficacy and plasma concentrations of tacrolimus, voriconazole, and repaglinide. We conducted a translational study to investigate if flucloxacillin induces CYP enzymes. We also investigated if flucloxacillin induces its own metabolism as an autoinducer. We performed a randomized, unblinded, two-period, cross-over, clinical pharmacokinetic cocktail study. Twelve healthy adults completed the study. They ingested 1 g flucloxacillin 3 times daily for 31 days, and we assessed the full pharmacokinetics of the Basel cocktail drugs on days 0, 10, and 28, and plasma concentrations of flucloxacillin on days 0, 9, and 27. The 3D spheroid of primary human hepatocytes (PHHs) were exposed to flucloxacillin (concentration range: 0.15-250 μM) for 96 hours. Induction of mRNA expression, protein abundance, and enzyme activity of CYP enzymes were assessed. Flucloxacillin treatment reduced the metabolic ratio of midazolam (CYP3A4), (geometric mean ratio (GMR) 10 days (95% confidence interval (CI)): 0.75 (0.64-0.89)) and (GMR 28 days (95% CI): 0.72 (0.62-0.85)). Plasma concentrations of flucloxacillin did not change during 27 days of treatment. Flucloxacillin caused concentration-dependent induction of CYP3A4 and CYP2B6 (mRNA, protein, and activity), CYP2C9 (mRNA and protein), CYP2C19 (mRNA and activity), and CYP2D6 (activity) in 3D spheroid PHH. In conclusion, flucloxacillin is a weak inducer of CYP3A4, which may lead to clinically relevant drug-drug interactions for some narrow therapeutic range drugs that are substrates of CYP3A4.
引用
- Iversen DB, Dunvald AD, Jespersen DM, et al. Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes. Clin Pharmacol Ther. 2023. PMID: 37235733. doi:10.1002/cpt.2959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。